Mesenchymal Stem Cells (MSCs) Transplantation for Diabetes: Where Do We Stand?

References

1. Desai SM Bhonde RR Veeranjaneyulu A Therapeutic potential of mesenchymal stem cells or their secretome in diabetic mice with or without preconditioning treatment. Recent Adv Inflamm Allergy Drug Discov 2025 19 Feb 10.2174/0127722708323777250121224618 39950288
   [Google Scholar]
2. Bobis S. Jarocha D. Majka M. Mesenchymal stem cells: Characteristics and clinical applications. Folia Histochem. Cytobiol. 2006 44 4 215 230 17219716
   [Google Scholar]
3. Berebichez-Fridman R. Montero-Olvera P.R. Sources and clinical applications of mesenchymal stem cells: State-of-the-art review. Sultan Qaboos Univ. Med. J. 2018 18 3 e264 e277 10.18295/squmj.2018.18.03.002 30607265
   [Google Scholar]
4. Xu Q. Hou W. Zhao B. Mesenchymal stem cells lineage and their role in disease development. Mol. Med. 2024 30 1 207 10.1186/s10020‑024‑00967‑9 39523306
   [Google Scholar]
5. Viswanathan S. Shi Y. Galipeau J. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy 2019 21 10 1019 1024 10.1016/j.jcyt.2019.08.002 31526643
   [Google Scholar]
6. Miclau K. Hambright W.S. Huard J. Stoddart M.J. Bahney C.S. Cellular expansion of MSCs: Shifting the regenerative potential. Aging Cell 2023 22 1 13759 10.1111/acel.13759 36536521
   [Google Scholar]
7. Song N. Scholtemeijer M. Shah K. Mesenchymal stem cell immunomodulation: Mechanisms and therapeutic potential. Trends Pharmacol. Sci. 2020 41 9 653 664 10.1016/j.tips.2020.06.009 32709406
   [Google Scholar]
8. Chen W. Lv L. Chen N. Cui E. Immunogenicity of mesenchymal stromal/stem cells. Scand. J. Immunol. 2023 97 6 13267 10.1111/sji.13267 39007962
   [Google Scholar]
9. Tao H. Han Z. Han Z.C. Li Z. Proangiogenic features of mesenchymal stem cells and their therapeutic applications. Stem Cells Int. 2016 2016 1 1314709 10.1155/2016/1314709 26880933
   [Google Scholar]
10. Banday M.Z. Sameer A.S. Nissar S. Pathophysiology of diabetes: An overview. Avicenna J. Med. 2020 10 4 174 188 10.4103/ajm.ajm_53_20 33437689
    [Google Scholar]
11. Schuster D.P. Duvuuri V. Diabetes mellitus. Clin. Podiatr. Med. Surg. 2002 19 1 79 107 10.1016/S0891‑8422(03)00082‑X 11806167
    [Google Scholar]
12. Harreiter J. Roden M. Diabetes mellitus: Definition, classification, diagnosis, screening and prevention (Update 2023). Wien. Klin. Wochenschr. 2023 135 Suppl. 1 7 17 10.1007/s00508‑022‑02122‑y 37101021
    [Google Scholar]
13. Bailes B.K. Diabetes mellitus and its chronic complications. AORN J. 2002 76 2 266 282 10.1016/s0001‑2092(06)61065‑x 12194653
    [Google Scholar]
14. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes–2018. Diabetes Care 2018 41 Suppl. 1 S13 S27 10.2337/dc18‑S002 29222373
    [Google Scholar]
15. Lucier J. Mathias P.M. Type 1 Diabetes. Treasure Island, FL StatPearls 2025
    [Google Scholar]
16. Taplin C.E. Barker J.M. Autoantibodies in type 1 diabetes. Autoimmunity 2008 41 1 11 18 10.1080/08916930701619169 18176860
    [Google Scholar]
17. Syed F.Z. Type 1 diabetes mellitus. Ann. Intern. Med. 2022 175 3 ITC33 ITC48 10.7326/AITC202203150 35254878
    [Google Scholar]
18. Riddell M.C. Gallen I.W. Smart C.E. Exercise management in type 1 diabetes: A consensus statement. Lancet Diabetes Endocrinol. 2017 5 5 377 390 10.1016/S2213‑8587(17)30014‑1 28126459
    [Google Scholar]
19. Goyal R. Singhal M. Jialal I. Type 2 Diabetes. Treasure Island, FL StatPearls 2025
    [Google Scholar]
20. Regufe V.M.G. Pinto C.M.C.B. Perez P.M.V.H.C. Metabolic syndrome in type 2 diabetic patients: A review of current evidence. Porto Biomed. J. 2020 5 6 101 10.1097/j.pbj.0000000000000101 33299950
    [Google Scholar]
21. Singh A. Shadangi S. Gupta P.K. Rana S. Type 2 diabetes mellitus: A comprehensive review of pathophysiology, comorbidities, and emerging therapies. Compr. Physiol. 2025 15 1 70003 10.1002/cph4.70003 39980164
    [Google Scholar]
22. Liakos A. Karagiannis T. Avgerinos I. Malandris K. Tsapas A. Bekiari E. Management of type 2 diabetes in the new era. Hormones 2023 22 4 677 684 10.1007/s42000‑023‑00488‑w 37700155
    [Google Scholar]
23. Kunarathnam V. Vadakekut E.S. Mahdy H. Gestational Diabetes. Treasure Island, FL StatPearls 2025
    [Google Scholar]
24. Kautzky-Willer A. Winhofer Y. Kiss H. Gestational diabetes mellitus (Update 2023). Wien. Klin. Wochenschr. 2023 135 Suppl. 1 115 128 10.1007/s00508‑023‑02181‑9 37101032
    [Google Scholar]
25. Forlenza G.P. Moran A. Nathan B. Other Specific Types of Diabetes. In: Howard V, Narayan KMV, Rewers M, Fradkin JE, Eds Diabetes in America. Howard V. Narayan K.M.V. Rewers M. Fradkin J.E. Bethesda, MD National Institute of Diabetes and Digestive and Kidney Diseases 2018 33651540
    [Google Scholar]
26. Cho J. D’Antuono M. Glicksman M. Wang J. Jonklaas J. A review of clinical trials: Mesenchymal stem cell transplant therapy in type 1 and type 2 diabetes mellitus. Am. J. Stem Cells 2018 7 4 82 93 30510843
    [Google Scholar]
27. Wu Z. Huang S. Li S. Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in patients with type 2 diabetes mellitus: A randomized controlled study with 8-year follow-up. Stem Cell Res. Ther. 2024 15 1 339 10.1186/s13287‑024‑03907‑w 39350270
    [Google Scholar]
28. Izadi M. Sadr Hashemi Nejad A. Moazenchi M. Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: A phase I/II randomized placebo-controlled clinical trial. Stem Cell Res. Ther. 2022 13 1 264 10.1186/s13287‑022‑02941‑w 35725652
    [Google Scholar]
29. Nguyen L.T. Hoang D.M. Nguyen K.T. Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow-derived mesenchymal stem/stromal cells. Stem Cells Transl. Med. 2021 10 9 1266 1278 10.1002/sctm.20‑0506 34080789
    [Google Scholar]
30. Bhansali S. Dutta P. Kumar V. Efficacy of autologous bone marrow-derived mesenchymal stem cell and mononuclear cell transplantation in type 2 diabetes mellitus: A randomized, placebo-controlled comparative study. Stem Cells Dev. 2017 26 7 471 481 10.1089/scd.2016.0275 28006991
    [Google Scholar]
31. Dantas J.R. Araújo D.B. Silva K.R. Adipose tissue-derived stromal/stem cells + cholecalciferol: A pilot study in recent-onset type 1 diabetes patients. Arch. Endocrinol. Metab. 2021 65 3 342 351 10.20945/2359‑3997000000368 33939911
    [Google Scholar]
32. Araujo D.B. Dantas J.R. Silva K.R. Allogenic adipose tissue-derived stromal/stem cells and vitamin d supplementation in patients with recent-onset type 1 diabetes mellitus: A 3-month follow-up pilot study. Front. Immunol. 2020 11 993 10.3389/fimmu.2020.00993 32582156
    [Google Scholar]
33. Zang L. Li Y. Hao H. Efficacy of umbilical cord-derived mesenchymal stem cells in the treatment of type 2 diabetes assessed by retrospective continuous glucose monitoring. Stem Cells Transl. Med. 2023 12 12 775 782 10.1093/stcltm/szad060 37738447
    [Google Scholar]
34. Wang Y. Chen H. Li Y. Predictive factors that influence the clinical efficacy of umbilical cord–derived mesenchymal stromal cells in the treatment of type 2 diabetes mellitus. Cytotherapy 2024 26 3 311 316 10.1016/j.jcyt.2023.12.006 38219142
    [Google Scholar]
35. Zang L. Li Y. Hao H. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: A single-center, double-blinded, randomized, placebo-controlled phase II trial. Stem Cell Res. Ther. 2022 13 1 180 10.1186/s13287‑022‑02848‑6 35505375
    [Google Scholar]
36. Chen P. Huang Q. Xu X.J. The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus. Zhonghua Nei Ke Za Zhi 2016 55 5 349 354 10.3760/cma.j.issn.0578‑1426.2016.05.004 27143183
    [Google Scholar]
37. Lian X.F. Lu D.H. Liu H.L. Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: A phase 2 clinical trial. World J. Clin. Cases 2023 11 21 5083 5096 10.12998/wjcc.v11.i21.5083 37583846
    [Google Scholar]
38. Lian X.F. Lu D.H. Liu H.L. Effectiveness and safety of human umbilical cord-mesenchymal stem cells for treating type 2 diabetes mellitus. World J. Diabetes 2022 13 10 877 887 10.4239/wjd.v13.i10.877 36312002
    [Google Scholar]
39. Lu J. Shen S. Ling Q. One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: An open parallel controlled clinical study. Stem Cell Res. Ther. 2021 12 1 340 10.1186/s13287‑021‑02417‑3 34112266
    [Google Scholar]
40. Wu Z. Xu X. Cai J. Prevention of chronic diabetic complications in type 1 diabetes by co-transplantation of umbilical cord mesenchymal stromal cells and autologous bone marrow: A pilot randomized controlled open-label clinical study with 8-year follow-up. Cytotherapy 2022 24 4 421 427 10.1016/j.jcyt.2021.09.015 35086778
    [Google Scholar]
41. Cai J. Wu Z. Xu X. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: A pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care 2016 39 1 149 157 10.2337/dc15‑0171 26628416
    [Google Scholar]
42. Gibbons C.H. Zhu J. Zhang X. Habboubi N. Hariri R. Veves A. Phase 2a randomized controlled study investigating the safety and efficacy of PDA ‐002 in diabetic peripheral neuropathy. J. Peripher. Nerv. Syst. 2021 26 3 276 289 10.1111/jns.12457 34169613
    [Google Scholar]